White Cell Transfer as Cancer Therapy
- Determine the safety of white blood cell infusion in patients with metastatic or
- Determine the efficacy of this therapy in these patients.
OUTLINE: Patients receive allogeneic white blood cell infusions once daily for 5-10
Patients undergo blood sample collection periodically for correlative laboratory studies.
The samples are evaluated by in vitro white cell kill assay before the first infusion,
immediately after the first infusion, on day 2, and then immediately after the last infusion
to assess in vitro cancer cell killing activity. Chimerism studies are performed before the
first infusion, immediately after the first infusion, and then on days 2 and 7. Complete
chimerism is assayed by short tandem repeat analysis using PCR. Patients with readily
accessible tumor tissue (e.g., cervical or axillary lymph nodes or subcutaneous tumor
nodules) may also undergo biopsy during the first week of treatment to demonstrate the
presence or absence of tumor infiltrating granulocytes.
After completion of study therapy, patients are followed periodically for 3 months.
Primary Purpose: Treatment
Zheng Cui, MD, PhD
Comprehensive Cancer Center of Wake Forest University